Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review evaluated the evidence on skin disorders linked to levodopa treatment for Parkinson's disease, suggesting a possible association with melanoma, though evidence remains inconclusive and further studies are needed.

This case report describes two postmenopausal women with Parkinson's disease who experienced reversible hair loss after using the dopamine agonists pramipexole and ropinirole.

A specific gene mutation is linked to a hereditary form of dystonia that responds well to certain medications.

In this study, 27.9% of Parkinson's disease patients reported hair loss, with a higher incidence linked to a daily levodopa-equivalent dose over 448 mg, suggesting an association between dopaminergic medication use and hair loss complaints.

This article reviews skin disorders in Parkinson's disease, highlighting the potential of skin studies and stem cell research to advance understanding and treatment of the neurodegenerative disorder, without presenting new results.

This study developed a new clustering model to improve detection of drug-induced cognitive disorder risk signals, finding that it identified drugs with moderate risk signals, like Carbidopa/Levodopa, missed by traditional methods, enhancing clinical assessment comprehensiveness.

This study found that finasteride significantly reduced levodopa-induced dyskinesia in both male and female rats without diminishing l-DOPA's motor benefits, indicating potential for clinical trials in Parkinson's patients.

This study reports that an electrochemical biosensor using a gold and palladium-modified electrode effectively detects levodopa and uric acid in various samples, offering improved performance over previous electrodes.

Pramipexole can cause side effects like dizziness, sleepiness, hallucinations, and low blood pressure, and it's important to educate patients and keep doses low.

This review discusses the potential antidepressant effects of phenylalanine, highlighting its significant activity in laboratory studies, but reports no new clinical findings.

This study observed no teratogenic effects of oral decongestants and surprisingly favorable neonatal outcomes in Swedish women who used them during pregnancy.

The interdisciplinary approach improved the quality of life for a Parkinson's patient and eased staff workload.

This review discusses medication-induced gray hair repigmentation, highlighting that certain anti-inflammatory drugs and melanogenesis stimulators can cause diffuse repigmentation, though evidence remains low-quality and these medications are not currently indicated for this purpose.

This study found that dopamine directly induces the catagen phase in human scalp hair follicles in vitro.

This report highlights a case where a woman's use of the dopamine agonist pramipexole for Parkinson's disease was associated with hair loss, which improved after discontinuing the drug.

This case report describes a patient with psoriasis who experienced scalp hair darkening and increased growth during anti–IL-17 therapy.

Albendazole can cause hair loss, and piroxicam can cause fixed drug eruption.

This article reviews over-the-counter products and active ingredients marketed for hair loss treatment, noting that many lack robust efficacy evidence except for minoxidil, which has temporary effects, and highlights the caution needed when recommending products to pregnant and breastfeeding women.

This article describes a clinical case of a 67-year-old patient with telogen effluvium treated with a supplement containing amino acids, vitamin E, iron, and Serenoa repens, but reports no new clinical findings.

This study reports that both a 9-month-old with phenylketonuria on a phenylalanine-free diet and mice on a deficient diet exhibited severe health issues, highlighting the need for cautious dietary management.

This study revealed significant signals of drug-related cognitive disorders in several medications that lack relevant FDA label warnings, suggesting a need for increased clinical awareness and potential label updates.

In this case report, an 80-year-old woman experienced darkening of previously grey hair, which may be linked to vitamin B supplementation, though its effectiveness is typically associated with reversing greying only in the presence of an initial vitamin B deficiency.

In this report, researchers document a rare case of a 16-year-old female on azathioprine presenting with both anagen effluvium and plica neuropathica, highlighting a unique instance of overlapping hair conditions potentially linked to medication use.

This case report details the challenging diagnostic journey of a 50-year-old woman with progressive supranuclear palsy, highlighting the disease's complex and variable clinical presentation.

This article reviews common disorders leading to hair loss in females and discusses their clinical features and management strategies, but it presents no new clinical results.

Some drugs can cause hair loss or growth, but hair usually returns to normal after stopping the drug.

This book reviews hair morphology, growth physiology, and hormonal influences but offers no new research findings and is critiqued for its inadequate index and distracting references.

This review discusses the neurobiology of sexual function and reports no new results; the authors cover multiple endocrine and neurotransmitter influences on sexual desire, arousal, and orgasm stages.

This article proposes five different mechanisms for telogen effluvium, supported by clinical findings, based on changes in different phases of the hair cycle.

Some drugs can cause hair loss or increase hair growth, but these effects are usually reversible when the drug is stopped.